A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Ankylosing Spondylitis

In brief

The aim of this study is to evaluate the efficacy and safety of LNK01001 in subjects with active ankylosing spondylitis. The study is comprised of a 16-week randomized, double-blind, parallel-group, placebo-controlled period (the Double-Blind Period); a 36-week open-label, long-term extension period (the Open-Label Extension Period). In the Double-Blind Period, participants will be randomized in a 1:1 ratio to receive either LNK01001 or placebo twice daily (BID). Participants in the placebo group will be switched to LNK01001 BID at Week 16 in the Open-Label Extension Period.

Key facts

Study ID
NCT07237568
Run by
Lynk Pharmaceuticals Co., Ltd
People needed
352
Starts
2025-08-29
Expected to finish
2027-09-01
Last updated by the study team
2025-11-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.